To include your compound in the COVID-19 Resource Center, submit it here.

Hearing loss trial of GenVec gene therapy clears hurdle

GenVec Inc. (NASDAQ:GNVC) rose $0.02 to $0.80 on Monday after partner Novartis AG (NYSE:NVS; SIX:NOVN)

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE